Items where authors include "Paller, A.S."

Article

Paller, A.S., Silverberg, J.I., Simpson, E.L. et al. (7 more authors) (2025) The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: results from a placebo-controlled, phase 3 study. Journal of the American Academy of Dermatology, 92 (1). pp. 116-126. ISSN 0190-9622

Paller, A.S., Ramien, M. orcid.org/0000-0001-9191-3611, Cork, M.J. orcid.org/0000-0003-4428-2428 et al. (9 more authors) (2024) Low infection rates with long‐term dupilumab treatment in patients aged 6 months to 5 years: an open‐label extension study. Pediatric Dermatology. ISSN 0736-8046

Paller, A.S. orcid.org/0000-0001-6187-6549, Siegfried, E.C., Simpson, E.L. et al. (7 more authors) (2024) Dupilumab safety and efficacy up to 1 Year in children aged 6 months to 5 years with atopic dermatitis: results from a phase 3 open-label extension study. American Journal of Clinical Dermatology, 25 (4). pp. 655-668. ISSN 1175-0561

Paller, A.S., Siegfried, E.C., Cork, M.J. orcid.org/0000-0003-4428-2428 et al. (7 more authors) (2024) Infections in children aged 6 months to 5 years treated with dupilumab in a placebo-controlled clinical trial of moderate-to-severe atopic dermatitis. Pediatric Drugs, 26 (2). pp. 163-173. ISSN 1174-5878

Paller, A.S. orcid.org/0000-0001-6187-6549, Siegfried, E.C., Cork, M.J. orcid.org/0000-0003-4428-2428 et al. (8 more authors) (2023) Laboratory safety from a randomized 16-week phase III study of dupilumab in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis. Pediatric Drugs, 25. pp. 67-77. ISSN 1174-5878

Blauvelt, A., Guttman-Yassky, E., Paller, A.S. et al. (13 more authors) (2022) Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis : results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE). American Journal of Clinical Dermatology, 23 (3). pp. 365-383. ISSN 1175-0561

Paller, A.S., Beck, L.A., Blauvelt, A. et al. (9 more authors) (2022) Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis—a pooled analysis of trial data. Pediatric Dermatology, 39 (2). pp. 187-196. ISSN 0736-8046

Simpson, E.L., Paller, A.S., Siegfried, E.C. et al. (10 more authors) (2021) Dupilumab demonstrates rapid and consistent improvement in extent and signs of atopic dermatitis across all anatomical regions in pediatric patients 6 years of age and older. Dermatology and Therapy, 11. pp. 1643-1656. ISSN 2193-8210

Paller, A.S., Wollenberg, A., Siegfried, E. et al. (12 more authors) (2021) Laboratory safety of dupilumab in patients aged 6–11 years with severe atopic dermatitis : results from a phase III clinical trial. Pediatric Drugs, 23 (5). pp. 515-527. ISSN 1174-5878

Abuabara, K., Nicholls, S.G., Langan, S.M. et al. (4 more authors) (2021) Priority research questions in atopic dermatitis : an International Eczema Council eDelphi consensus. British Journal of Dermatology, 185 (1). pp. 203-205. ISSN 0007-0963

Paller, A.S., Siegfried, E.C., Simpson, E.L. et al. (12 more authors) (2021) A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. Journal of the European Academy of Dermatology and Venereology, 35 (2). pp. 464-475. ISSN 0926-9959

Paller, A.S., Siegfried, E.C., Thaçi, D. et al. (22 more authors) (2020) Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. Journal of the American Academy of Dermatology, 83 (5). pp. 1282-1293. ISSN 0190-9622

Thyssen, J.P., de Bruin-Weller, M.S., Paller, A.S. et al. (14 more authors) (2019) Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion. Journal of the European Academy of Dermatology and Venereology, 33 (7). pp. 1224-1231. ISSN 0926-9959

Leshem, Y.A., Bissonnette, R., Paul, C. et al. (5 more authors) (2019) Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey-based position statement. Journal of the European Academy of Dermatology and Venereology, 33 (5). pp. 807-815. ISSN 0926-9959

Simpson, E.L., Reynolds, N.J., Flohr, C. et al. (5 more authors) (2018) Response to "Comment on: 'When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council'''. Journal of The American Academy of Dermatology, 79 (2). E25-E26. ISSN 0190-9622

Simpson, E.L., Bruin-Weller, M., Flohr, C. et al. (26 more authors) (2017) When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. Journal of The American Academy of Dermatology, 77 (4). pp. 623-633. ISSN 0190-9622

Luger, T., Boguniewicz, M., Carr, W. et al. (22 more authors) (2015) Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants. Pediatric Allergy and Immunology, 26 (4). pp. 306-315. ISSN 0905-6157